Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

CELU - Celularity Inc. So'nggi Yangiliklar | Finranks

Home

CELU

C

Celularity Inc. (CELU)

NCM – Real vaqt narxi. Valyuta: USD

1.22

+0.02 (1.67%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

1.18

-0.04 (-3.28%)

Bozordan keyin: Mar 27, 2026, 7:50 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today reiterated that its strategic commercialization partnership with NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement clarity around placental-derived biomaterials and build sales and market share. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue

The transaction represents the most significant milestone in the company's history.

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits.

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz

Celularity Announces Closing of Financing Transactions

Celularity Announces Closing of Financing Transactions

FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP.

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convertible note financing with Philip A. Barach, co-founder and former president of DoubleLine Capital LP, a Los Angeles-based investment management firm. The contemplated financing transactions are contingent upon the parties executing formal transaction agreements, which the parties expect to do shortly.

Videolar

No Data

There is no data to display

Press-relizlar

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

FLORHAM PARK, N.J., March 12, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today reiterated that its strategic commercialization partnership with NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL) is a focused effort by the two companies to rapidly capitalize on renewed regulatory and reimbursement clarity around placental-derived biomaterials and build sales and market share. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions.

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits.

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations

While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz While Celularity's Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz